Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Posted
Frank Vinluan (via MedCity News)
Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a majority stake in Aurion Biotech, a startup developing a corneal cell therapy.
The post Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition appeared first on MedCity News.
